Literature DB >> 33826325

A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer.

Alicia Corlett1, Marc-Antoine Sani, Jessica Van Zuylekom2, Ching-Seng Ang3, Elisabeth von Guggenberg4, Carleen Cullinane2,5, Benjamin Blyth2,5, Rodney J Hicks2,5, Peter D Roselt6, Philip E Thompson7, Craig A Hutton, Mohammad B Haskali5,6.   

Abstract

Proteins adopt unique folded secondary and tertiary structures that are responsible for their remarkable biological properties. This structural complexity is key in designing efficacious peptides that can mimic the three-dimensional structure needed for biological function. In this study, we employ different chemical strategies to induce and stabilize a β-hairpin fold of peptides targeting cholecystokinin-2 receptors for theranostic application (combination of a targeted therapeutic and a diagnostic companion). The newly developed peptides exhibited enhanced folding capacity as demonstrated by circular dichroism (CD) spectroscopy, ion-mobility spectrometry-mass spectrometry, and two-dimensional (2D) NMR experiments. Enhanced folding characteristics of the peptides led to increased biological potency, affording four optimal Ga-68 labeled radiotracers ([68Ga]Ga-4b, [68Ga]Ga-11b-13b) targeting CCK-2R. In particular, [68Ga]Ga-12b and [68Ga]Ga-13b presented improved metabolic stability, enhanced cell internalization, and up to 6 fold increase in tumor uptake. These peptides hold great promise as next-generation theranostic radiopharmaceuticals.

Entities:  

Year:  2021        PMID: 33826325     DOI: 10.1021/acs.jmedchem.0c02213

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

Review 1.  Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals.

Authors:  Elisabeth von Guggenberg; Petra Kolenc; Christof Rottenburger; Renata Mikołajczak; Alicja Hubalewska-Dydejczyk
Journal:  Cancers (Basel)       Date:  2021-11-18       Impact factor: 6.575

2.  Automated Synthesis of 68Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting.

Authors:  Anton Amadeus Hörmann; Elisabeth Plhak; Maximilian Klingler; Christine Rangger; Joachim Pfister; Gert Schwach; Herbert Kvaternik; Elisabeth von Guggenberg
Journal:  Molecules       Date:  2022-03-21       Impact factor: 4.927

3.  Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study.

Authors:  Berthold A Nock; Panagiotis Kanellopoulos; Oleg G Chepurny; Maritina Rouchota; George Loudos; George G Holz; Eric P Krenning; Theodosia Maina
Journal:  Pharmaceutics       Date:  2022-03-18       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.